방법 비교
선택한 방법을 나란히 검토하세요. 서로 다른 행은 강조 표시됩니다.
| 비용효과 분석 (CEA)× | 삶의 질 보정 생명년수 (QALY)× | |
|---|---|---|
| 분야 | 보건경제학 | 보건경제학 |
| 계열 | Process / pipeline | Process / pipeline |
| 기원 연도≠ | 1984 | 1985 |
| 창시자≠ | Drummond & Stoddart (Health Economics Research Group, McMaster University) | Alan Williams (Health Economics Research Centre, Oxford University) |
| 유형 | Method | Method |
| 원전≠ | Gold, M. R., Siegel, J. E., Russell, L. B., & Weinstein, M. C. (Eds.). (1996). Cost-Effectiveness in Health and Medicine. New York: Oxford University Press. link ↗ | Kind, P. (1989). The EuroQol instrument: an index of health-related quality of life. In B. Teeling Smith (Ed.), Measuring health: a practical approach. Chichester: Wiley. link ↗ |
| 별칭≠ | CEA, ICER, Incremental Cost-Effectiveness Ratio | QALY, health utility measure |
| 관련 | 5 | 5 |
| 요약≠ | Cost-effectiveness analysis compares the incremental cost per unit of health benefit gained by one intervention relative to a comparator (standard care or best alternative). Developed rigorously in the 1980s by Drummond, Stoddart, and colleagues, CEA is now the standard framework for technology appraisal globally. NICE, HAS, CADTH, and other health technology assessment bodies use CEA to decide which treatments warrant public funding and at what price. | A QALY measures health benefit as utility weight (0 = death, 1 = perfect health) multiplied by time lived. Developed by Alan Williams in 1985, QALYs enable comparison of disparate health interventions on a common metric. Used globally by health technology assessment bodies—NICE (UK), HAS (France), CADTH (Canada), WHO—to decide which treatments deserve public funding. |
| ScholarGate데이터셋 ↗ |
|
|